Suppr超能文献

评估 AMU 和抗耐甲氧西林金黄色葡萄球菌药物使用的替代指标:基于日本国民健康保险索赔和特定健康检查数据库的数据研究。

An alternative index for evaluating AMU and anti-methicillin-resistant Staphylococcus aureus agent use: A study based on the National Database of Health Insurance Claims and Specific Health Checkups data of Japan.

机构信息

Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University, 5 Misasagi-Nakauchi-cho, Yamashina-ku, Kyoto-shi, Kyoto, 607-8414, Japan.

AMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan, 1-21-1 Toyama Shinjuku-ku, Tokyo, 162-8655, Japan.

出版信息

J Infect Chemother. 2021 Jul;27(7):972-976. doi: 10.1016/j.jiac.2021.02.009. Epub 2021 Feb 19.

Abstract

INTRODUCTION

Anti-methicillin-resistant Staphylococcus aureus (MRSA) agents have different doses and administration periods. Thus, it is difficult to evaluate antimicrobial use (AMU) of anti-MRSA agents using defined daily doses per 1000 inhabitants per day (DID) or days of therapy per 1000 inhabitants per day (DOTID). This study aimed to evaluate the relationship between anti-MRSA agent use and resistant bacteria using the number of patients per 1000 inhabitants per day (PID) as an alternative index of AMU.

METHODS

AMU data for anti-MRSA agents were collected from the National Database of Health Insurance Claims and Specific Health Checkups (NDB) in 2016. The relationship between PID and DID or DOTID was evaluated. The number of patients with MRSA isolated was obtained from Japan Nosocomial Infections Surveillance, and their correlation with PID was analyzed. The rate of anti-MRSA agent use in each prefecture was investigated.

RESULTS

PID showed a significant linear relationship with both DID and DOTID (all p < 0.0001). PID was significantly correlated with the number of patients with MRSA isolated. Additionally, the rate of anti-MRSA agent use was markedly different in each region.

CONCLUSIONS

PID is not affected by doses and administration periods, and thus may be an alternative index for the selective pressure of antibiotics. Evaluating AMU using PID based on NDB data will help in the development of effective antimicrobial resistance measures.

摘要

简介

抗耐甲氧西林金黄色葡萄球菌(MRSA)药物的剂量和给药周期不同。因此,使用每千名居民每天的限定日剂量(DID)或每千名居民每天的治疗天数(DOTID)来评估抗 MRSA 药物的抗菌药物使用(AMU)是很困难的。本研究旨在使用每千名居民每天的患者人数(PID)作为 AMU 的替代指标,评估抗 MRSA 药物使用与耐药菌之间的关系。

方法

2016 年从国民健康保险索赔和特定健康检查全国数据库(NDB)中收集了抗 MRSA 药物的 AMU 数据。评估了 PID 与 DID 或 DOTID 的关系。从日本医院感染监测中获得了分离出的 MRSA 患者人数,并分析了它们与 PID 的相关性。还调查了每个县的抗 MRSA 药物使用率。

结果

PID 与 DID 和 DOTID 均呈显著线性关系(均 p<0.0001)。PID 与分离出的 MRSA 患者人数显著相关。此外,抗 MRSA 药物的使用率在各个地区存在显著差异。

结论

PID 不受剂量和给药周期的影响,因此可能是抗生素选择压力的替代指标。使用基于 NDB 数据的 PID 评估 AMU 将有助于制定有效的抗菌药物耐药性措施。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验